Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Nov 21, 2017 8:34pm
152 Views
Post# 27007989

RE:RE:RE:New MDR cases

RE:RE:RE:New MDR casesJF,

Clinically, we’re seeing a lot of that in the IV drug user population.

Even if they are using clean needles, they tend to reuse filters which harbour the virus. It’s leading to an epidemic of a sort.

I have no concerns that Ibalizumab will have a market...it’s up to the reps to get it out there.

As for the share price rise the past few days, I agree it is a reaction to the article.

Luc, known to be conservative, is stating the blue sky speciality pharma case for TH.

Why wouldn’t new buyers pay 5% more tomorrow if the CEO is confident in huge revenues and a few more drugs down the line?

bfw


jfm1330 wrote: Cases of patients using Truvada as PrEP are reported in the litterature, but be sure there are transmission in a lot of other case.

People uninfected or already infected  not taking any ARV drugs. Infected patients already infected, but on drugs the MDR virus resist to.

Remember. Some MDR patients got there because they were in many clinical trials using drugs as monotherapy, but many other got there because they had poor behavior concerning adherence. The same pattern of irresponsible conduct can lead some to have unprotected relations with unaware partners. 

All that to say that these MDR strains are still transmitted, so no need for the long process of drug resistance to unfold in the patient body over the years. He can be given an already made MDR virus in one shot.


Bullboard Posts